|
Includes all of these presentations from this session:
| # |
Presentation |
Speaker |
| 1 |
What are the levels of evidence? |
H.H. Wang (Boston) |
| 2 |
How is screening for esophageal squamous cell carcinoma performed in China? |
S. Dawsey (NCI, Bethesda) |
| 3 |
Can endo-cytoscopy replace biopsy histology for squamous cell carcinoma? |
Y. Kumagai (Saitama) |
| 4 |
Does the incidence of adenocarcinoma justify surveillance in individuals who have gastro-esophageal reflux disease or Barrett?s esophagus? |
J.M. Inadomi (Seattle) |
| 5 |
Evidence-Based decision making in Esophageal Cancer |
J.M. Inadomi (Seattle) |
| 6 |
What are the current nonendoscopic options for early detection and treatment of esophageal squamous cell carcinoma and its precursor lesions? |
S. Dawsey (NCI, Bethesda) |
| 7 |
Is there a minimum number of lymph nodes from resected specimens required for accurate staging of the esophageal carcinoma? |
R.M. Najarian (Boston) |
| 8 |
What is the clinical significance of post-therapy pathologic stage in patients with esophageal adenocarcinoma following preoperative chemoradiation? |
H.H. Wang (Boston) |
| 9 |
What is the clinical significance of posttherapy pathologic stage in patients with esophageal squamous cell carcinoma following preoperative chemoradiation? |
Yin-Kai Chao (Taiwan) |
| 10 |
Can stimulation of salivary and esophageal secretion of protective factors help to prevent RE, BE & adenocarcinoma sequelae in patients with gastro-esophageal reflux disease? |
J. Sarosiek (El Paso) |
|
